RVPH - Reviva Pharmaceuticals, Inc. Price/Earnings to Growth Ratio
The innovative brilaroxazine pipeline for treating schizophrenia is driving the price action for Reviva Pharmaceuticals (RVPH). The PEG ratio dynamics visualize this volatility, where 0.00 reflects the latest value of the metric. Partnerships with institutes developing new antipsychotics and a closed physician support ecosystem, which minimizes patient churn to alternatives, strengthen the fundamentals.
Reviva Pharmaceuticals (RVPH) - metric breakdowns and financial figures
- current quotes and average value forecast:
- market capitalization statistics:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Total Debt to Capital Reviva Pharmaceuticals|RVPH - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital revivapharma.com|RVPH - Company Debts|Debts to Book Capitalization Ratio Reviva Pharmaceuticals Holdings|RVPH - Company Long-Term Debts|Company Short-Term Loans and Borrowings Reviva Pharmaceuticals|Quick Ratio revivapharma.com
- net income and valuation ratios data:
RVPH - Company Net Income|Expected Net Income Reviva Pharmaceuticals|RVPH - Price to Earnings Ratio|Projected Price to Earnings Reviva Pharmaceuticals, Inc.|RVPH - PEG Multiple|EV/EBITDA Multiple Reviva Pharmaceuticals Holdings|RVPH - Operating profit EBITDA|Net earnings per share for the last 12 months Reviva Pharmaceuticals|RVPH - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months revivapharma.com|RVPH - Net earnings per share growth this year|Earnings growth forecast for next year Reviva Pharmaceuticals
- sales revenue and business income indicators:
Fundamental company analysis:Reviva Pharmaceuticals Holdings Inc. - RVPH
The PEG ratio compares the P/E multiple with earnings growth rates to determine the fairness of the current price. Values below one signal that an asset is undervalued relative to its expansion. Analyzing the ratio of valuation to earnings dynamics allows investors to filter out speculative noise from fundamental trends. This chart is critically important for Reviva Pharmaceuticals (RVPH). The growth potential here is embedded in the synergy with partners upon the completion of Phase III trials for Brinavazine.
Competing companies
BIIB - Price to Earnings Adjusted for Growth Rate|Neurocrine Biosciences Inc - Price/Earnings to Growth Multiple|Regencell Corp - Price/Earnings to Growth Ratio|Axsome Therapeutics - PEG Multiple|Growth-Adjusted Market Cap to Net Income acadia-pharm.com ACAD|XENE (Xenon) - Price/Earnings to Growth Multiple|VKTX (Viking Therapeutics Inc) - Price/Earnings to Growth Ratio|SUPN (Supernus Pharma) - PEG Multiple|PEG Multiple Catalyst Corp|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics)|HRMY (harmonybiosciences.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Biohaven BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Market Cap to Earnings and Growth Ratio|Trevi Pharma - PEG Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Corp)|AVXL: PEG Multiple|ceribell.com (CBLL) - PEG Multiple|Price/Earnings to Growth Ratio Prothena Corporation plc|ALEC: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|Price/Earnings to Growth Multiple omeros.com OMER|PEG Multiple NGNE (Neurogene Inc.)|PEG Multiple acimmune.com ACIU|Voyager Therapeutics, Inc. - PEG Multiple|Neumora (NMRA) - Price/Earnings to Growth Multiple|SCLX: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tevogen Bio Inc. (TVGN)|Price/Earnings to Growth Multiple ACOG|PEG Multiple cogrx.com|Price/Earnings to Growth Multiple IKT (Inhibikase Therapeutics, Inc.)|Company Value to Earnings Growth Ratio SAVA|PEG Multiple ASRT (Assertio)|Growth-Adjusted Market Cap to Net Income Coya Therapeutics Inc (COYA)|VistaGen Therapeutics Inc - PEG Multiple|Ovid Therapeutics Inc. (OVID) - Price/Earnings to Growth Multiple|ABOS: PEG Multiple|CervoMed, Inc. (CRVO) - PEG Multiple|Price/Earnings to Growth Ratio Alterity Therapeutics Ltd.|Price/Earnings to Growth Ratio CLNN|Price/Earnings to Growth Ratio PepGen Inc. (PEPG)|Growth-Adjusted Market Cap to Net Income jupiterneurosciences.com|Price/Earnings to Growth Ratio Relmada Therapeutics, Inc. RLMD|Growth-Adjusted Payback Ratio ANVS|GRCE: Price/Earnings to Growth Multiple|AIFF: Price/Earnings to Growth Ratio|anewmeds.com (KLTO) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NRSN (NeuroSense Therapeutics Ltd.)|MTVA (MetaVia Inc.) - PEG Multiple|NRXS: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Helius Medical (HSDT)|passagebio.com - Growth-Adjusted P/E Ratio|PEG Multiple NEUP (Neuphoria Therapeutics)|minervaneurosciences.com (NERV) - Price to Earnings Adjusted for Growth Rate|ATHA: Price/Earnings to Growth Multiple|ADXN - PEG Multiple|alzamend.com (ALZN) - Price/Earnings to Growth Ratio|Cyclerion Therapeutics, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|Price to Earnings Adjusted for Growth Rate Pasithea KTTA|Price/Earnings to Growth Ratio Cortigent, Inc. (CRGT)|ATXI (Avenue Therapeutics Inc.) - Growth-Adjusted Payback Ratio|PEG Multiple BCLI (Brainstorm Cell Therapeutics, Inc.)|Cara Therapeutics Inc (CARA) - Price to Earnings Adjusted for Growth Rate|CHRO: Price/Earnings to Growth Multiple|ELYM: Price/Earnings to Growth Ratio|ITCI: PEG Multiple|LBPH - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple MRNS|Price/Earnings to Growth Ratio NKGN|PEG Multiple NRBO|PEG Multiple sagerx.com (SAGE)|Synaptogenix - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio TRVN|VIGL - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio WENA|CERE: PEG Multiple
